Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research…
Events
ThirtyFiveBio data debut: AACR 2023 poster presentation
ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James Westcott, presented…
GWT to present preclinical data on first-in-class ERAP1 Inhibitors at SITC
Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).